Skolkovo to further support HIV drug development

Print 04 April 2016
Marchmont Innovation News

The Skolkovo Foundation, which is managing Russia’s most widely touted innovation hub just outside Moscow, has approved a new $2.2m grant for the next stage of the development and commercialization of a Russian innovative solution to fight HIV, the Foundation  announced  in its press release. 

The grant will go to Viriom, a biomedical developer and asset of the ChemRar High Tech Center in Khimki outside Moscow. The company has been working on Russia’s first HIV solution which is expected to go beyond import substitution—an across-the-board goal the Russians have been pursuing in many sectors since the current crisis and western sanctions began—and offer “high potential for international commercialization.” 

The new drug candidate’s safety, high efficacy and tolerance are said to have been proven during five rounds of phases 1 and 2 clinical trial testing. Phase 3 of clinical trials is currently under way in 18 AIDS prevention centers across Russia. 

In 2015, the Skolkovo Foundation gave its resident companies $24+m worth of grants, with 17% of these supporting micro- and minigrants, according to the press release. Private sector co-funding accounted for 47% of the total.

Source

Return